Literature DB >> 17461930

Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.

E Castoldi1, P Simioni, D Tormene, M C L G D Thomassen, L Spiezia, S Gavasso, J Rosing.   

Abstract

BACKGROUND: Hyperprothrombinemia, resulting from the prothrombin G20210A mutation or other causes, is associated with activated protein C (APC) resistance and increased thrombosis risk. When high prothrombin levels are a result of increased hepatic biosynthesis, these effects may be counteracted by concomitantly increased levels of the anticoagulant factors (particularly protein S). Differently, in prothrombin G20210A carriers only prothrombin levels are elevated.
OBJECTIVE: To investigate whether prothrombin G20210A carriers have a more severe hypercoagulable state than non-carriers with comparable prothrombin levels. PATIENTS/
METHODS: Coagulation factor levels, thrombin generation (Calibrated Automated Thrombogram in the presence and absence of APC) and APC resistance were measured in normal (n = 132), heterozygous (n = 167) and homozygous (n = 3) individuals.
RESULTS: Prothrombin levels, thrombin generation and APC resistance were higher in carriers of the prothrombin G20210A mutation (especially those who had experienced venous thrombosis) than in non-carriers, whereas protein S and antithrombin levels were similar among genotype groups. Because individuals with high prothrombin levels in the absence of the prothrombin G20210A mutation tend to have all liver-synthesized factors elevated, carriers of the mutation had lower protein S and antithrombin levels than non-carriers with equally high prothrombin levels. Accordingly, they also generated more thrombin and showed a tendency toward higher APC resistance. Analogous effects, but less pronounced, were observed in homozygotes for the prothrombin A19911G polymorphism, which also upregulates prothrombin levels.
CONCLUSIONS: Individuals with hyperprothrombinemia as a result of prothrombin gene mutations generate more thrombin and tend to be more APC-resistant than individuals with comparable prothrombin levels because of other causes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461930     DOI: 10.1111/j.1538-7836.2007.02448.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Functional polymorphisms of the coagulation factor II gene (F2) and susceptibility to systemic lupus erythematosus.

Authors:  F Yesim K Demirci; Amy S Dressen; Candace M Kammerer; M Michael Barmada; Amy H Kao; Rosalind Ramsey-Goldman; Susan Manzi; M Ilyas Kamboh
Journal:  J Rheumatol       Date:  2011-01-15       Impact factor: 4.666

2.  Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

Authors:  Elisabetta Castoldi; Lisbeth F A Maurissen; Daniela Tormene; Luca Spiezia; Sabrina Gavasso; Claudia Radu; Tilman M Hackeng; Jan Rosing; Paolo Simioni
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

4.  Placental prothrombin mRNA levels in APC resistance (APCR) women with increased placental fibrin deposition.

Authors:  S Sedano-Balbas; M Lyons; B Cleary; M Murray; G Gaffney; M Maher
Journal:  Ir J Med Sci       Date:  2013-12-22       Impact factor: 1.568

5.  Elevated prothrombin promotes venous, but not arterial, thrombosis in mice.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Jian-Guo Wang; Matthew J Heisler; Kellie R Machlus; Brian C Cooley; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

Review 6.  Prothrombin G20210A Gene Mutation-Induced Recurrent Deep Vein Thrombosis and Pulmonary Embolism: Case Report and Literature Review.

Authors:  Sherif Elkattawy; Ramez Alyacoub; Kerry S Singh; Hardik Fichadiya; William Kessler
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

7.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23

8.  Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

Authors:  Charles L Percy; Rudolf Hartmann; Rhidian M Jones; Subramaniam Balachandran; Dheeraj Mehta; Michael Dockal; Friedrich Scheiflinger; Valerie B O'Donnell; Judith E Hall; Peter W Collins
Journal:  Blood Coagul Fibrinolysis       Date:  2015-06       Impact factor: 1.276

9.  Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations.

Authors:  Rita Carolina Figueiredo Duarte; Cláudia Natália Ferreira; Danyelle Romana Alves Rios; Helton José Dos Reis; Maria das Graças Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-09

10.  Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples.

Authors:  William C Chang; Joseph W Jackson; Kellie R Machlus; Alisa S Wolberg; Mikhail V Ovanesov
Journal:  Res Pract Thromb Haemost       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.